Octreotide News and Research

RSS

Deep-water cone snails produce a potentially painkilling compound, study reports

Scientists already know that the venom of cone snails, which prowl the ocean floor for a fish dinner, contains compounds that can be adapted as pharmaceuticals to treat chronic pain, diabetes and other human maladies.

24 Mar 2022

Investigational oral form of treatment offers hope for adults with acromegaly

Adults who need medical maintenance treatment of the growth hormone disorder acromegaly respond well to an investigational oral form of the drug octreotide, investigators of the Chiasma OPTIMAL study reported.

31 Mar 2020

New FDA-approved therapy provides better quality of life for patients with midgut neuroendocrine tumors

Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy.

12 Jun 2018

FDA approves new radioactive drug for treatment of rare digestive tract cancers

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

29 Jan 2018

Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

Malignant neuroendocrine tumors, commonly called NETs, are easy to miss and associated with discouraging survival rates and poor quality of life.

13 Jun 2017

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Aggressive neuroendocrine cancer is something of a dark horse--a rare, elusive and persevering force linked to discouraging long-term survival rates.

14 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Ga-68 DOTATATE PET/CT scans more effective than current imaging standard for detecting NETS

A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors, and could significantly impact treatment management.

10 May 2016

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

A novel drug proven to reduce the risk of disease progression by 79% as well as three new European Centres of Excellence, offer new hope to patients with inoperable metastatic advanced midgut neuroendocrine cancer.

11 Mar 2016

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.

7 Oct 2015

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines, today announced that it has entered a collaboration with German biotechnology company Cilian AG to develop a solid dose formulation of Cilian's experimental recombinant influenza vaccine, CiFlu, for delivery using Glide's patient-friendly SDI delivery device.

21 Sep 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).

24 Apr 2015

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

24 Apr 2015

Chiasma closes $70 million Series E financing round

Chiasma, Inc., a U.S. privately-held biopharma company developing octreotide capsules, its lead product for the orphan condition acromegaly, today announced the closing of a $70 million Series E financing round.

27 Feb 2015

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Chiasma Inc., a U.S. privately-held biopharma company, announced today that results from a multicenter Phase III study of the investigational new drug, octreotide capsules, were published online for early release on Feb. 9, ahead of print, by the Journal of Clinical Endocrinology & Metabolism.

10 Feb 2015

Researchers identify a single protein as root cause of multiple allergic reactions

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can be found that targets the problematic protein, they say, it could help smooth treatment for patients with conditions ranging from prostate cancer to diabetes to HIV

17 Dec 2014

Octreotide News and Research

Deep-water cone snails produce a potentially painkilling compound, study reports

Investigational oral form of treatment offers hope for adults with acromegaly

New FDA-approved therapy provides better quality of life for patients with midgut neuroendocrine tumors

FDA approves new radioactive drug for treatment of rare digestive tract cancers

Novel peptide receptor radionuclide therapy improves wellbeing of neuroendocrine cancer patients

Molecular imaging technique could help optimize radiotherapy dose to combat NETs

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Ga-68 DOTATATE PET/CT scans more effective than current imaging standard for detecting NETS

New development offers hope to patients with inoperable advanced midgut neuroendocrine cancer

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Glide Technologies, Cilian collaborate to develop solid dose formulation of recombinant influenza vaccine

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Glide's solid dose formulation of teriparatide achieves successful results in pre-clinical study

Chiasma closes $70 million Series E financing round

Chiasma announces publication of octreotide capsules Phase III study results in JCEM

Researchers identify a single protein as root cause of multiple allergic reactions

Rare neuroendocrine tumours may be misdiagnosed as Cushing’s disease

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Chemotherapy may benefit advanced pulmonary carcinoid tumour patients

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News